Comprehensive characterization of cytochrome P450 isozyme selectivity across chemical libraries

Nature Biotechnology

Volumn 27, Issue 11, 2009, Pages 1050-1055

  Veith, Henrike ^a   Southall, Noel ^a   Huang, Ruili ^a   James, Tim ^b   Fayne, Darren ^b   Artemenko, Natalia ^b   Shen, Min ^a   Inglese, James ^a   Austin, Christopher P ^a   Lloyd, David G ^b   Auld, Douglas S ^a  

^a NATIONAL INSTITUTES OF HEALTH   (United States)

^b TRINITY COLLEGE DUBLIN   (Ireland)

Author keywords

[No Author keywords available]

Indexed keywords

BIOACTIVATION; BIOLUMINESCENT ASSAY; CHEMICAL LIBRARIES; COMMON PROPERTY; CYP 2D6; CYTOCHROME P450; DRUG DEVELOPMENT; DRUG METABOLISMS; GENE FAMILIES; IN-VITRO; PHARMACOLOGICAL PROPERTIES; US FOOD AND DRUG ADMINISTRATION;

LIBRARIES;

CYTOCHROME P450;

ARTICLE; BIOLUMINESCENCE; ENZYME ACTIVITY; ENZYME ANALYSIS; ENZYME INHIBITION; IN VITRO STUDY; PRIORITY JOURNAL;

CLUSTER ANALYSIS; CYTOCHROME P-450 ENZYME SYSTEM; HIGH-THROUGHPUT SCREENING ASSAYS; HUMANS; ISOENZYMES; SMALL MOLECULE LIBRARIES; SUBSTRATE SPECIFICITY;

EID: 70449370313     PISSN: 10870156     EISSN: 15461696     Source Type: Journal    
DOI: 10.1038/nbt.1581     Document Type: Article

References (50)

1. Evans, W.E. & Relling, M.V. Pharmacogenomics: translating functional genomics into rational therapeutics. Science 286, 487-491 (1999).
2. Ortiz de Montellano, P.R. (ed.) Cytochrome P450: structure, mechanism, and biochemistry. (Kluwer Acedemic/Plenum Publishers, New York, 2005).
3. Williams, J.A. et al. Drug-drug interactions for UDP- glucuronosyltransferase substrates: a pharmacokinetic explanation for typically observed low exposure (AUCi/ AUC) ratios. Drug Metab. Disp. 32, 1201-1208 (2004).
4. Di, L. & Kerns, E.H. Application of pharmaceutical profling assays for optimization of drug-like properties. Curr. Opin. Drug Discov. Devel. 8, 495-504 (2005).
5. Hollenberg, P.F. Characteristics and common properties of inhibitors, inducers, and activators of CYP enzymes. Drug Metab. Rev. 34, 17-35 (2002).
6. Lewis, D.F., Eddershaw, P.J., Dickins, M., Tarbit, M.H. & Goldfarb, P.S. Structural determinants of cytochrome P450 substrate specifcity, binding affnity and catalytic rate. Chem. Biol. Interact. 115, 175-199 (1998).
7. Porter, T.D. & Coon, M.J. Cytochrome P-450. Multiplicity of isoforms, substrates, and catalytic and regulatory mechanisms. J. Biol. Chem. 266, 13469-13472 (1991).
8. Sigel, A. et al. The Ubiquitous Roles of Cytochrome P450 Proteins: Metal Ions in Life Sciences vol. 3. (John Wiley & Sons, Ltd., 2007).
9. Rendic, S. Summary of information on human CYP enzymes: human P450 metabolism data. Drug Metab. Rev. 34, 83-448 (2002).
10. Inglese, J. et al. Quantitative high-throughput screening: A titration-based approach that effciently identifes biological activities in large chemical libraries. Proc. Natl. Acad. Sci. USA 103, 11473-11478 (2006).
11. Zheng, W. et al. Three classes of glucocerebrosidase inhibitors identifed by quantitative high-throughput screening are chaperone leads for Gaucher disease. Proc. Natl. Acad. Sci. USA 104, 13192-13197 (2007).
12. Auld, D.S. et al. A basis for reduced chemical library inhibition of frefy luciferase obtained from directed evolution. J. Med. Chem. 52, 1450-1458 (2009).
13. Davis, R.E. et al. A cell-based assay for IκBα stabilization using a two-color dual luciferase-based sensor. Assay Drug Dev. Technol. 5, 85-104 (2007).
14. Xia, M. et al. Compound cytotoxicity profling using quantitative high-throughput screening. Environ. Health Perspect. 116, 284-291 (2008).
15. Cali, J.J. et al. Luminogenic cytochrome P450 assays. Expert Opin. Drug Metab. Toxicol. 2, 629-645 (2006).
16. Lipinski, C.A. Drug-like properties and the causes of poor solubility and poor permeability. J. Pharmacol. Toxicol. Methods 44, 235-249 (2000).
17. Chauret, N. et al. Description of a 96-well plate assay to measure cytochrome P4503A inhibition in human liver microsomes using a selective fuorescent probe. Anal. Biochem. 276, 215-226 (1999).
18. Kenworthy, K.E., Bloomer, J.C., Clarke, S.E. & Houston, J.B. CYP3A4 drug interactions: correlation of 10 in vitro probe substrates. Br. J. Clin. Pharmacol. 48, 716-727 (1999).
19. Kohonen, T. Self-organizing neural projections. Neural Netw. 19, 723-733 (2006).
20. Kohonen, T. & Oja, E. Computing with neural networks. Science 235, 1227a (1987).
21. Lewis, D.F.V. A Guide to Cytochrome P450 Structure and Function (Taylor & Francis, London, 2001).
22. Foti, R.S. & Wahlstrom, J.L. CYP2C19 inhibition: the impact of substrate probe selection on in vitro inhibition profles. Drug Metab. Dispos. 36, 523-528 (2008).
23. Kumar, V. et al. CYP2C9 inhibition: impact of probe selection and pharmacogenetics on in vitro inhibition profles. Drug Metab. Dispos. 34, 1966-1975 (2006).
24. Nath, A. & Atkins, W.M. Principal component analysis of CYP2C9 and CYP3A4 probe substrate/inhibitor panels. Drug Metab. Dispos. 36, 2151-2155 (2008).
25. Shimada, T. et al. Cytochrome P450-dependent drug oxidation activities in liver microsomes of various animal species including rats, guinea pigs, dogs, monkeys, and humans. Arch. Toxicol. 71, 401-408 (1997).
26. Shimada, T., Yamazaki, H., Mimura, M., Inui, Y. & Guengerich, F.P. Inter-individual variations in human liver cytochrome P-450 enzymes involved in the oxidation of drugs, carcinogens and toxic chemicals: studies with liver microsomes of 30 Japanese and 30 Caucasians. J. Pharmacol. Exp. Ther. 270, 414-423 (1994).
27. Wienkers, L.C. & Heath, T.G. Predicting in vivo drug interactions from in vitro drug discovery data. Nat. Rev. Drug Discov. 4, 825-833 (2005).
28. Lewis, D.F. & Ito, Y. Human cytochromes P450 in the metabolism of drugs: new molecular models of enzyme-substrate interactions. Expert Opin. Drug Metab. Toxicol. 4, 1181-1186 (2008).
29. de Graaf, C., Pospisil, P. , Pos, W., Folkers, G. & Vermeulen, N.P. Binding mode prediction of cytochrome p450 and thymidine kinase protein-ligand complexes by consideration of water and rescoring in automated docking. J. Med. Chem. 48, 2308-2318 (2005).
30. de Graaf, C., Vermeulen, N.P. & Feenstra, K.A. Cytochrome p450 in silico: an integrative modeling approach. J. Med. Chem. 48, 2725-2755 (2005).
31. Ekins, S., de Groot, M.J. & Jones, J.P. Pharmacophore and three-dimensional quantitative structure activity relationship methods for modeling cytochrome p450 active sites. Drug Metab. Dispos. 29, 936-944 (2001)
32. Hansch, C., Leo, A., Mekapati, S.B. & Kurup, A. QSAR and ADME. Bioorg. Med. Chem. 12, 3391-3400 (2004).
33. Hansch, C., Mekapati, S.B., Kurup, A. & Verma, R.P. QSAR of cytochrome P450. Drug Metab. Rev. 36, 105-156 (2004).
34. Fox, T. & Kriegl, J.M. Linear quantitative structure-activity relationships for the interaction of small molecules with human cytochrome P450 isoenzymes. Annual Reports in Computational Chemistry vol.3 (eds. Spellmeyer, D. and Wheeler, R.) 64-84, (Elsevier, New York, 2007).
35. Yasgar, A. et al. Compound management for quantitative high-throughput screening. J. Assoc. Lab. Autom. 13, 79-89 (2008).
36. Shukla, S.J. et al. Identifcation of pregnane X receptor ligands using time-resolved fuorescence resonance energy transfer and quantitative high-throughput screening. Assay Drug Dev. Technol. 7, 143-169 (2009).
37. Feng, B.Y. et al. A high-throughput screen for aggregation-based inhibition in a large compound library. J. Med. Chem. 50, 2385-2390 (2007).
38. Goode, D.R., Totten, R.K., Heeres, J.T. & Hergenrother, P.J. Identifcation of promiscuous small molecule activators in high-throughput enzyme activation screens. J. Med. Chem. 51, 2346-2349 (2008).
39. Shoichet, B.K. Interpreting steep dose-response curves in early inhibitor discovery. J. Med. Chem. 49, 7274-7277 (2006).
40. Eagling, V.A., Tjia, J.F. & Back, D.J. Differential selectivity of cytochrome P450 inhibitors against probe substrates in human and rat liver microsomes. Br. J. Clin. Pharmacol. 45, 107-114 (1998).
41. von Moltke, L.L. et al. Phenacetin O-deethylation by human liver microsomes in vitro: inhibition by chemical probes, SSRI antidepressants, nefazodone and venlafaxine. Psychopharmacology (Berl.) 128, 398-407 (1996).
42. Zhang, J.H., Chung, T.D. & Oldenburg, K.R. A simple statistical parameter for use in evaluation and validation of high throughput screening assays. J. Biomol. Screen. 4, 67-73 (1999).
43. Huang, R. et al. Characterization of diversity in toxicity mechanism using in vitro cytotoxicity assays in quantitative high throughput screening. Chem. Res. Toxicol. 21, 659-667 (2008).
44. Eastwood, B.J. et al. The minimum signifcant ratio: a statistical parameter to characterize the reproducibility of potency estimates from concentration-response assays and estimation by replicate-experiment studies. J. Biomol. Screen. 11, 253-261 (2006).
45. Weininger, D. Smiles, a chemical language and information system. 1. Introduction to methodology and encoding rules. J. Chem. Inf. Comput. Sci. 28, 31-36 (1988).
46. Kohonen, T. The self-organizing map. Neurocomputing 21, 1-6 (1998).
47. Arimoto, R., Prasad, M.A. & Gifford, E.M. Development of CYP3A4 inhibition models: comparisons of machine-learning techniques and molecular descriptors. J. Biomol. Screen. 10, 197-205 (2005).
48. Cohen, L.H., Remley, M.J., Raunig, D. & Vaz, A.D. In vitro drug interactions of cytochrome p450: an evaluation of fuorogenic to conventional substrates. Drug Metab. Dispos. 31, 1005-1015 (2003).
49. Schulz, M. & Schmoldt, A. Therapeutic and toxic blood concentrations of more than 800 drugs and other xenobiotics. Pharmazie 58, 447-474 (2003).
50. Zlokarnik, G., Grootenhuis, P.D. & Watson, J.B. High throughput P450 inhibition screens in early drug discovery. Drug Discov. Today 10, 1443-1450 (2005)